3SBio Inc. (1530.HK) stock analysis
In our weekly check, 3SBio Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 1, red flags: 5.
About 3SBio Inc.
3SBio Inc. is a Healthcare company (Biotechnology) based in China, listed on HKSE as 1530.HK.
What our checks show for 1530.HK
Red flags
- Analysts expect revenue to shrink about 14.5% a year.
- Analysts expect the net margin to shrink by 21.4 points from today's 47.9%.
- The price swings a lot: 57.2% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 79% from a peak. Would you have held through that?
- Recovering from its deepest fall took about 3.1 years.
Warning signs
- Analysts expect earnings per share to shrink about 30.4% a year.
Strengths
- Debt is low: 0.05x equity.
- Operating profit covers interest 21.3 times over.
- The net margin rose by 22.1 points over 5 years, to 47.9%.
- The gross margin is 92.4% and has risen by 9.7 points: pricing power is holding.
- Revenue grew 37.1% a year over the last 3 years.
- Earnings per share grew 63.8% a year over the last 3 years.
Similar companies
GMAB · 9995.HK · ONC · RVMDW · ROIV · UTHR
Questions
What grade does 3SBio Inc. (1530.HK) have?
In our weekly check, 3SBio Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 1, red flags: 5. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of 1530.HK stock?
This week's biggest flags for 3SBio Inc.: Weak revenue forecast, Margins expected to shrink, Very volatile. In total 6 of 25 checks show a warning or a red flag.
What does 3SBio Inc. do?
3SBio Inc. is a Healthcare company (Biotechnology) based in China, listed on HKSE as 1530.HK.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-10-31
Open the full analysis